Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need


Letter to Shareholders - Change in Company Name
 May 11, 2020

Trovagene, Inc. announced the change in its company name to Cardiff Oncology, Inc. For additional information, please download the Letter to Shareholders.